For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
8
views
Article has an altmetric score of 3
58
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      288
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis

      systematic-review

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          This study aimed to evaluate the effectiveness and safety of Allisartan Isoproxil in the management of hypertension.

          Methods

          A comprehensive search was conducted across both English and Chinese databases, including the Cochrane Library, Embase, PubMed, Web of Science, Chinese Journal Full Text Database (CNKI), Wanfang Digital Periodical Full Text Database, and VIP Chinese Periodical Database (VIP), up to March 24, 2024. Randomized controlled trials (RCTs) investigating alisartan axetil for hypertension management were selected. Literature quality was assessed, and data were extracted for meta-analysis using Stata 15.1 software. The quality of evidence for outcome indicators was evaluated using the GRADE system level.

          Results

          Six RCTs involving 767 participants were included. Meta-analysis revealed that, compared to placebo, the Allisartan Isoproxil group exhibited a significant reduction in systolic blood pressure (SBP) [WMD = −8.08, 95% CI (−11.81, 4.10), p = 0.000] and brachial-ankle pulse wave velocity (baPWV) [SMD = −0.69, 95% CI (−1.17, 0.20), p = 0.006]. However, the reduction in diastolic blood pressure (DBP) was not statistically significant [WMD = −5.48, 95% CI (−11.07, 0.10), p = 0.054]. Additionally, compared to calcium channel blockers (CCB) and angiotensin II receptor blockers (ARB), Allisartan Isoproxil did not significantly affect SBP [WMD = 0.20, 95% CI (−3.71, 4.10), p = 0.921] or DBP [WMD = 0.16, 95% CI (−2.11, 2.43), p = 0.891]. Allisartan Isoproxil demonstrated superior effects in increasing nitric oxide (NO) levels and decreasing endothelin (ET) levels compared to control groups [WMD = 9.56, 95% CI (6.42, 12.71), p = 0.000], [WMD = −7.42, 95% CI (−11.13, −3.71), p = 0.000], and showed a higher effective control rate of blood pressure [RR = 1.26, 95% CI (1.13, 1.41), p = 0.000]. Subgroup analysis did not reveal significant differences. Regarding safety, there were no statistically significant differences in adverse events between the Allisartan Isoproxil group and the control groups [RR = 0.99, 95% CI (0.74, 1.32), p = 0.928], and no fatal adverse events were reported.

          Conclusion

          Allisartan Isoproxil is effective in reducing SBP and baPWV, increasing NO, decreasing ET, and achieving a higher control rate of blood pressure in patients with essential hypertension. These benefits are achieved with minimal adverse reactions.

          Systematic Review Registration

          https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023467869, identifier PROSPERO CRD42023467869.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

          Matthew J L Page, Joanne E McKenzie, Patrick Bossuyt … (2027)
          The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.
          Article 0 comments Cited 19468 times – based on 0 reviews     Review now
          Article has an altmetric score of 682
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)

            Giuseppe Mancia(Chairperson), Reinhold Kreutz(Co-Chair), Mattias Brunström … (2023)
            Article 0 comments Cited 465 times – based on 0 reviews     Review now
            Article has an altmetric score of 981
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement

              George S. Stergiou, Paolo Palatini, Gianfranco Parati … (2021)
              Article 0 comments Cited 236 times – based on 0 reviews     Review now
              Article has an altmetric score of 390
                Bookmark
                All references

                Author and article information

                Contributors
                Fengfeng Zhao: URI : https://loop.frontiersin.org/people/2603620/overviewRole: Role: Role: Role: Role: Role:
                Yihua Liu: Role: Role: Role: Role: Role: Role:
                Liang Chen: URI : https://loop.frontiersin.org/people/2272943/overviewRole: Role: Role: Role: Role: Role:
                Journal
                Journal ID (nlm-ta): Front Cardiovasc Med
                Journal ID (iso-abbrev): Front Cardiovasc Med
                Journal ID (publisher-id): Front. Cardiovasc. Med.
                Title: Frontiers in Cardiovascular Medicine
                Publisher: Frontiers Media S.A.
                ISSN (Electronic): 2297-055X
                Publication date (Electronic): 06 June 2024
                Publication date Collection: 2024
                Volume: 11
                Electronic Location Identifier: 1355014
                Affiliations
                [ 1 ]School of Clinical Medicine, Shandong Second Medical University , Weifang, Shandong, China
                [ 2 ]Department of Adult Internal Medicine, Qingdao Women’s and Children’s Hospital , Qingdao, Shandong, China
                Author notes

                Edited by: Qianman Peng, Harvard Medical School, United States

                Reviewed by: Jing Yu, Lanzhou University Second Hospital, China

                Konstantinos Kyriakoulis, National and Kapodistrian University of Athens, Greece

                [* ] Correspondence: Liang Chen qdfe102777@ 123456126.com
                Article
                DOI: 10.3389/fcvm.2024.1355014
                PMC ID: 11187348
                PubMed ID: 38903964
                SO-VID: b16e49b0-dd62-4099-9312-5a5df4a3f880
                Copyright © © 2024 Zhao, Liu and Chen.
                License:

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                Date received : 13 December 2023
                Date accepted : 27 May 2024
                Page count
                Figures: 11, Tables: 1, Equations: 0, References: 59, Pages: 18, Words: 0
                Funding
                The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
                Categories
                Subject: Cardiovascular Medicine
                Subject: Systematic Review
                Custom metadata
                section-at-acceptance Hypertension

                Keywords: allisartan isoproxil,hypertension,meta-analysis,systematic review,randomized controlled trial
                Data availability:
                Keywords: allisartan isoproxil, hypertension, meta-analysis, systematic review, randomized controlled trial

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content288

                See all similar

                Most referenced authors1,314

                See all reference authors